Literature DB >> 7658287

Treatment of essential thrombocythemia with anagrelide.

M M Chintagumpala1, L L Kennedy, C P Steuber.   

Abstract

Essential thrombocythemia (ET) is a myeloproliferative disorder characterized by persistent elevation in platelet count. It is a rare disorder in children, and children who have symptoms require treatment. We report the successful use of anagrelide, with few toxic effects, in the treatment of three children with ET.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658287     DOI: 10.1016/s0022-3476(95)70090-0

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

Review 1.  Anagrelide: a review of its use in the management of essential thrombocythaemia.

Authors:  Antona J Wagstaff; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.

Authors:  Vikas Dua; Satya Prakash Yadav; Vijay Kumar; Renu Saxena; Anupam Sachdeva
Journal:  Int J Hematol       Date:  2012-10-07       Impact factor: 2.490

Review 3.  Polycythaemia vera and essential thrombocythaemia: current treatment strategies.

Authors:  Elisabeth I Penninga; Ole W Bjerrum
Journal:  Drugs       Date:  2006       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.